Applied DNA to Showcase Linea IVT as a High-yield, dsRNA-Mitigated Platform for the GMP Manufacture of RNA at the 3rd Annual mRNA Process Development & Manufacturing Summit
Applied DNA Sciences (NASDAQ:APDN) announced its participation in the 3rd Annual mRNA Process Development & Manufacturing Summit in Boston from September 17-19, 2024. The company will showcase its Linea™ IVT platform, a solution for faster and better mRNA production with reduced double-stranded RNA contamination.
LineaRx, a majority-owned Applied DNA company, will present the platform, which combines an enzymatically produced DNA template with a next-generation RNA polymerase. Additionally, LineaRx and mRNA CDMO partner Kudo Biotechnology will co-host a seminar luncheon on September 19 to present data demonstrating Linea IVT's capability for rapid manufacturing of dsRNA-mitigated mRNA.
Applied DNA Sciences (NASDAQ:APDN) ha annunciato la sua partecipazione al 3° Summit annuale sullo sviluppo e la produzione di mRNA a Boston dal 17 al 19 settembre 2024. L'azienda presenterà la sua Linea™ IVT platform, una soluzione per una produzione di mRNA più veloce e migliore, con una riduzione della contaminazione da RNA a doppio filamento.
LineaRx, una società controllata da Applied DNA, presenterà la piattaforma, che combina un modello di DNA prodotto enzimaticamente con una polimerasi RNA di nuova generazione. Inoltre, LineaRx e il partner mRNA CDMO Kudo Biotechnology co-organizzeranno un pranzo seminario il 19 settembre per presentare dati che dimostrano la capacità della Linea IVT per la produzione rapida di mRNA mitigato da dsRNA.
Applied DNA Sciences (NASDAQ:APDN) anunció su participación en la 3ª Cumbre Anual sobre Desarrollo y Fabricación de mRNA en Boston del 17 al 19 de septiembre de 2024. La empresa exhibirá su plataforma Linea™ IVT, una solución para una producción de mRNA más rápida y de mejor calidad, con menor contaminación de ARN de doble cadena.
LineaRx, una empresa de Applied DNA de la que posee la mayoría, presentará la plataforma, que combina un molde de ADN producido enzimáticamente con una polimerasa de ARN de nueva generación. Además, LineaRx y su socio de CDMO de mRNA Kudo Biotechnology co-organizarán un almuerzo seminario el 19 de septiembre para presentar datos que demuestran la capacidad de la Linea IVT para la fabricación rápida de mRNA mitigado por dsRNA.
Applied DNA Sciences (NASDAQ:APDN)는 2024년 9월 17일부터 19일까지 보스턴에서 열리는 제3회 mRNA 프로세스 개발 및 제조 정상 회담에 참가한다고 발표했습니다. 이 회사는 이중 가닥 RNA 오염을 줄이면서 더 빠르고 나은 mRNA 생산을 위한 솔루션인 Linea™ IVT 플랫폼을 선보일 예정입니다.
Applied DNA의 지분 대부분을 소유하고 있는 LineaRx가 이 플랫폼을 발표할 것이며, 이는 효소적으로 생산된 DNA 템플릿과 차세대 RNA 중합효소를 결합합니다. 또한, LineaRx와 mRNA CDMO 파트너인 Kudo Biotechnology가 9월 19일 세미나 중식을 공동 주최하여 Linea IVT의 dsRNA 완화 mRNA의 신속한 제조 능력을 입증하는 데이터를 발표할 것입니다.
Applied DNA Sciences (NASDAQ:APDN) a annoncé sa participation au 3ème Sommet annuel sur le développement et la fabrication de l'ARNm à Boston du 17 au 19 septembre 2024. L'entreprise présentera sa plaqueforme Linea™ IVT, une solution pour une production d'ARNm plus rapide et de meilleure qualité, avec une réduction de la contamination par l'ARN double brin.
LineaRx, une société majoritairement détenue par Applied DNA, présentera la plateforme, qui combine un modèle d'ADN produit enzymatiquement avec une ARN polymérase de nouvelle génération. De plus, LineaRx et son partenaire mRNA CDMO Kudo Biotechnology co-organiseront un déjeuner séminaire le 19 septembre pour présenter des données démontrant la capacité de la Linea IVT à produire rapidement de l'ARNm atténué par de l'ARN double brin.
Applied DNA Sciences (NASDAQ:APDN) gab seine Teilnahme am 3. Jahresgipfel zur Entwicklung und Herstellung von mRNA in Boston vom 17. bis 19. September 2024 bekannt. Das Unternehmen wird seine Linea™ IVT-Plattform präsentieren, eine Lösung für eine schnellere und bessere mRNA-Produktion mit reduzierter Kontamination durch doppelsträngige RNA.
LineaRx, ein Mehrheitsunternehmen von Applied DNA, wird die Plattform vorstellen, die eine enzymatisch produzierte DNA-Vorlage mit einer RNA-Polymerase der nächsten Generation kombiniert. Darüber hinaus werden LineaRx und der mRNA CDMO-Partner Kudo Biotechnology am 19. September ein Seminar-Mittagessen veranstalten, um Daten zu präsentieren, die die Fähigkeit von Linea IVT zur schnellen Herstellung von dsRNA-mitigation mRNA zeigen.
- Participation in a major mRNA industry event, potentially increasing visibility and networking opportunities
- Showcasing Linea™ IVT platform, which offers faster and improved mRNA production
- Partnership with Kudo Biotechnology for a co-hosted seminar, demonstrating practical applications of their technology
- None.
- Co-Hosts Seminar with mRNA CDMO Kudo Bio to Demonstrate Linea IVT Capability for Rapid mRNA Manufacturing -
STONY BROOK, NY / ACCESSWIRE / September 17, 2024 / Applied DNA Sciences, Inc. (NASDAQ:APDN) (Applied DNA), a leader in PCR-based DNA technologies, today announced its participation at upcoming mRNA events in Boston this week:
3rd Annual mRNA Process Development & Manufacturing Summit - members of Applied DNA's Biotherapeutics Sales and Business Development teams (collectively 'LineaRx,' a majority-owned Applied DNA company) will attend the 3rd Annual mRNA Process Development & Manufacturing Summit taking place September 17-19, 2024.
LineaRx will present its Linea™ IVT platform - a combination of an enzymatically produced DNA template (Linea™ DNA IVT template) coupled with a next-generation RNA polymerase (Linea™ RNAP) - as a solution to enable mRNA producers to manufacture better mRNA faster via simplified workflows and reduced double-stranded RNA (dsRNA) contamination.
Lunch/Learn with Kudo Biotechnology - LineaRx and mRNA CDMO partner Kudo Biotechnology will co-host a seminar luncheon to present data from a proof-of-concept study and a case study to demonstrate how Linea IVT can support rapid manufacturing of dsRNA-mitigated mRNA. The Lunch/Learn will be held on Thursday, September 19, from 11:00 a.m. - 2:00 p.m. ET at MassBio and will be webcast-accessible here.
About the Linea™ DNA and Linea™ IVT Platforms
The Linea DNA platform is an entirely cell-free DNA production platform founded on Applied DNA's long-standing expertise in the large-scale enzymatic production of DNA. Capable of producing DNA in quantities ranging from milligrams to grams, the Linea DNA platform can produce high-fidelity DNA constructs ranging from 100bp to 20kb in size. The DNA produced via the Linea DNA platform is free of the adventitious DNA sequences found in other sources of DNA, is rapidly scalable, and provides for simple chemical modification of DNA constructs.
The Linea IVT platform combines DNA IVT templates manufacturing via the Linea DNA platform with a proprietary Linea™ RNAP to enable mRNA and sa-mRNA manufacturers to produce what Applied DNA believes to be better mRNA faster, with advantages over conventional mRNA production, including: 1) the elimination of plasmid DNA as a starting material; 2) the prevention or reduction of double-stranded DNA (dsRNA) contamination; and 3) simplified mRNA production workflows.
About LineaRx
LineaRx, an Applied DNA Sciences, Inc. (NASDAQ: APDN) company, was formed in 2018 to commercialize the parent company's 20+ years of experience in polymerase chain reaction ('PCR')-based DNA manufacturing and leadership in enzymatic DNA production. To learn more about Linea™ DNA: click here
About Applied DNA Sciences
Applied DNA Sciences is a biotechnology company developing technologies to produce and detect deoxyribonucleic acid ("DNA"). Using the polymerase chain reaction ("PCR") to enable both the production and detection of DNA, we operate in three primary business markets: (i) the enzymatic manufacture of synthetic DNA for use in the production of nucleic acid-based therapeutics and the development and sale of a proprietary RNA polymerase ("RNAP") for use in the production of mRNA therapeutics; (ii) the detection of DNA and RNA in molecular diagnostics and genetic testing services; and (iii) the manufacture and detection of DNA for industrial supply chain security services.
Visit adnas.com for more information. Follow us on X and LinkedIn. Join our mailing list.
Forward-Looking Statements
The statements made by Applied DNA in this press release may be "forward-looking" in nature within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995. Forward-looking statements describe Applied DNA's future plans, projections, strategies, and expectations, and are based on assumptions and involve a number of risks and uncertainties, many of which are beyond the control of Applied DNA. Actual results could differ materially from those projected due to its history of net losses, the unknown future demand for its biotherapeutics products and services, the unknown amount of revenues and profits that will result from its Linea IVT and or Linea DNA platforms, the fact that there has never been a commercial drug product utilizing PCR-produced DNA technology and/or the Linea IVT platform approved for therapeutic use, and various other factors detailed from time to time in Applied DNA's SEC reports and filings, including its Annual Report on Form 10-K, as amended, filed on December 7, 2023, and Quarterly Report on Form 10-Q filed on February 8, 2024, May 10, 2024, and August 8, 2024, and other reports it files with the SEC, which are available at www.sec.gov. Applied DNA undertakes no obligation to update publicly any forward-looking statements to reflect new information, events, or circumstances after the date hereof or to reflect the occurrence of unanticipated events, unless otherwise required by law.
Contacts:
Investor Relations contact: Sanjay M. Hurry, 917-733-5573, sanjay.hurry@adnas.com
Program contact: Clay Shorrock, 631-912-6454, clay.shorrock@adnas.com
Web: www.adnas.com
Twitter: @APDN
SOURCE: Applied DNA Sciences
View the original press release on accesswire.com
FAQ
What is Applied DNA Sciences showcasing at the 3rd Annual mRNA Process Development & Manufacturing Summit?
When and where is Applied DNA Sciences (APDN) participating in the mRNA summit?
What is the Linea™ IVT platform offered by Applied DNA Sciences (APDN)?
When is Applied DNA Sciences (APDN) co-hosting a seminar with Kudo Biotechnology?
